Significant Changes in Healthcare Policies and Programs for 2027

One in three women under 50 years old in the U.S. struggles with iron deficiency, impacting approximately 10 million people. Expert physicians are actively discussing effective management strategies. Concurrently, rheumatologists are addressing the challenges of rheumatoid arthritis, focusing on its painful symptoms and joint deformities.

The Joy in Medicine® Health System Recognition Program is designed to combat burnout among healthcare providers. It provides comprehensive guidelines to support medical teams, led by Dr. Jason Mitchell, who emphasizes innovation to enhance patient care.

The AMA ChangeMedEd® initiative promotes diversity and inclusion in medical education through innovative projects. Resources are available to guide medical professionals in the residency-selection process. An example is Dr. Buzick, who values the support from University of Iowa Health Care as he begins his oncology practice post-fellowship.

At the National Rx and Illicit Drug Summit, leaders like AMA President Dr. Bobby Mukkamala reinforced the importance of collaborative efforts in tackling the opioid crisis. Organizations such as AMA, ASAM, and APhA advocate for improved access to comprehensive care, urging flexibility in methadone prescriptions to enhance addiction treatment.

The CMS has released the CY 2027 Medicare Advantage and Part D final rule, featuring key changes for healthcare providers. The AMA praised the rule for excluding unlinked chart review records from risk score calculations, ensuring accurate Medicare Advantage payments. Notable provisions include continuity of care protections for dual-eligible beneficiaries and a moderate payment increase.

Despite positive changes, the final rule's weakened accountability measures have drawn AMA criticism. Concerns include the omission of the Health Equity Index reward and the removal of certain utilization management requirements. The rule introduces a strategy for identifying opioid "outlier" prescribers, though exemptions exist for palliative care cases.

The CMS has delayed specific prior authorization processes under the WISeR Model, giving healthcare providers additional preparation time. Meanwhile, the CDC has issued a warning regarding medetomidine found in illegal drug supplies. Healthcare professionals are urged to stay informed through AMA communications for essential policy updates and medical advancements.